Skip to main navigation
In order to offer and provide a customized and personal service through our products and websites, we may use cookies to store and help track information about you. ×
Logo

PIONEERING IMMUNOTHERAPY

SEC Filings

SEC Filing Keyword Search

Filing date Form Description Filing Group View
November 07, 2019 10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
0001564590-19-041741.rtf
View HTML
0001564590-19-041741.pdf
0001564590-19-041741.xls
EX-101.INS - XBRL INSTANCE DOCUMENT
November 07, 2019 8-K

Report of unscheduled material events or corporate event

Current Reports
0001564590-19-041752.rtf
View HTML
0001564590-19-041752.pdf
0001564590-19-041752.xls
September 27, 2019 8-K

Report of unscheduled material events or corporate event

Current Reports
0001193125-19-257413.rtf
View HTML
0001193125-19-257413.pdf
0001193125-19-257413.xls
September 18, 2019 4

Statement of changes in beneficial ownership of securities

3,4,5
0001567619-19-018506.rtf
View HTML
0001567619-19-018506.pdf
September 17, 2019 4

Statement of changes in beneficial ownership of securities

3,4,5
0001567619-19-018457.rtf
View HTML
0001567619-19-018457.pdf
0001567619-19-018457.xls
September 17, 2019 4

Statement of changes in beneficial ownership of securities

3,4,5
0001567619-19-018455.rtf
View HTML
0001567619-19-018455.pdf
0001567619-19-018455.xls
September 17, 2019 4

Statement of changes in beneficial ownership of securities

3,4,5
0001567619-19-018458.rtf
View HTML
0001567619-19-018458.pdf
0001567619-19-018458.xls
September 17, 2019 4

Statement of changes in beneficial ownership of securities

3,4,5
0001567619-19-018456.rtf
View HTML
0001567619-19-018456.pdf
August 01, 2019 8-K

Report of unscheduled material events or corporate event

Current Reports
0001564590-19-027964.rtf
View HTML
0001564590-19-027964.pdf
0001564590-19-027964.xls
August 01, 2019 10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
0001564590-19-027956.rtf
View HTML
0001564590-19-027956.pdf
0001564590-19-027956.xls
EX-101.INS - XBRL INSTANCE DOCUMENT

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »

In This Section

  • SEC Filings
  • Annual Reports

Investor Toolkit

  • Print Page
  • RSS Feeds
  • Email Alerts

Investor Relations

  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Analyst Coverage
  • Stock Information
  • FAQs
  • Home
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Global Headquarters
    • Community Affairs
  • Pipeline
    • Clinical Trials
    • Access to Our Investigational Agents
  • Technology
    • Immunotherapy
    • STING Pathway
    • APRIL Pathway
    • Scientific Publications
    • Intellectual Property
  • Partnerships
  • Media
    • Press Releases
  • Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Analyst Coverage
    • Stock Information
    • FAQs
  • Careers
  • Contact
  • Home
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Global Headquarters
    • Community Affairs
  • Pipeline
    • Clinical Trials
    • Access to Our Investigational Agents
  • Technology
    • Immunotherapy
    • STING Pathway
    • APRIL Pathway
    • Scientific Publications
    • Intellectual Property
  • Partnerships
  • Media
    • Press Releases
  • Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Analyst Coverage
    • Stock Information
    • FAQs
  • Careers
  • Contact
  • Privacy Policy
  • Terms and Conditions of Use
Logo© 2019 Aduro BiotechAll rights reserved
  • Privacy Policy
  • Terms and Conditions of Use
Website Design: Hane Chow, Inc.
TwitterLinkedIn